World Companion Diagnostics Summit Europe

frankfurt, Germany
Keywords: Biomarkers, Companion Diagnostics, Translational Research, Personalized Medicine, Molecular, Experimental medicine, Global medical affairs, Clinical strategy/development

Schedule of Presentations:

Monday, March 26, 2012
Tuesday, March 27, 2012
08:00:00 Registration, coffee and networking
09:00:00 Chairman’s opening remarks Richard Buller
09:05:00 Development, Approval and Commercialisation of CDx for Xalkori® (crizotinib) Richard Buller
09:35:00 Considerations for Finding Biomarkers and Translating into Diagnostics Along Side Drug Development
10:05:00 Speed networking session
11:00:00 Morning refreshments
11:30:00 Roche Personalised Healthcare: Identifying Key Factors for the Success of a Personalised Medicine Approach Gerd Maass
12:00:00 Successful Strategies in Personalised Medicine: Learning from a Global IVD Company
12:30:00 Lunch
13:30:00 Strategies for the Development of Personalised Medicine in Oncology: Exploring the Opportunities and Challenges
14:00:00 Drug-Diagnostic Co-Development: Why is it Important? Jan Trøst Jørgensen
14:30:00 Issues and Prospects for Companion Diagnostics in Oncology
15:00:00 Infectious Diseases: Implementing New Host Biomarker Research Findings into Clinical Development of New Hepatitis C Treatment Options
15:30:00 Afternoon refreshments
16:00:00 Personalised Healthcare in Oncology Drug Discovery & Development at Roche Martin Steegmaier
16:30:00 Analysis of Intrasubject Variability in CSF Biomarker Levels from Clinical Trials for Alzheimer’s Disease Jeffrey F. Waring
17:00:00 Stratified Medicine Approaches in Fertility and Endocrinology Therapeutic Areas: Implementation of Clinical Biomarker and Pharmacogenomics Strategy
17:30:00 Trials and Tribulations - Biomarkers and Diagnostics in Clinical Development
18:00:00 Chairman’s closing remarks
19:30:00 Networking dinner
Wednesday, March 28, 2012
08:00:00 Registration, coffee and networking
09:00:00 Chairman’s opening remarks Doris Ann Williams
09:05:00 Understanding Developments in European Regulation and Health Technology Assessment Management: What Does this Mean for Oncology Drug and Diagnostic Development in Europe? Lothar Bergmann
09:35:00 Marketing Authorisation Applications for Personalised Medicines: Regulators’ View and Expectations
10:05:00 Navigating the Evolving Regulatory Framework for Biomarker Qualification and Personalised Medicine: The Pharma Experience
10:35:00 Personalised Medicine and Companion diagnostics: The EU perspective Alexander Natz
11:05:00 Morning refreshments
11:35:00 Personalised Medicine in Europe 2020: Research, Innovation and Regulatory Challenges
12:05:00 Diagnostics Activities at NICE and the Assessment of Companion Diagnostics Nick Crabb
12:35:00 Lunch
13:45:00 Health Technology Assessment of Companion Diagnostics: The Cost-Benefit Balance Doris Ann Williams
14:15:00 Delivering a Companion Diagnostic to Market: Overcoming Market Access Challenges and Key Factors for Success Alain Huriez
14:45:00 Challenges of Companion Diagnostics from the Point of View of a Practicing Oncologist
16:15:00 A Unified Strategy for Personalised Medicines: The Formation of New R&D Partnerships Louise Leong
16:45:00 Chairman’s closing remarks
Thursday, March 29, 2012
08:00:00 Registration, coffee and networking
09:00:00 Chairman’s opening remarks
09:05:00 The Strategic Implementation of Biomarkers in Pharmaceuticals to Drive Decision-Making and Provide Candidates for Stratified Medicine
09:35:00 Predictive Diagnostics for Oncology Drug Development: The Small Pharma/Biotech Perspective
10:05:00 Translating Biomarkers from the Laboratory to the Clinic: Moving Towards Patient Stratification
10:35:00 Morning refreshments
11:05:00 Point of Care Diagnostics: Challenges, Value as Companion Diagnostics and Impact in Drug Development Jorge Villacian
11:35:00 Circulating Specific MicroRNA Biosignature for Diagnosis and Monitoring of Breast Cancer Treatment Michael Berndt
12:05:00 Specific Applications of Different Molecular Diagnostics Technologies to Optimise Drug Development: The Promise of Next Generation Sequencing Vladimir Lazar
12:35:00 Lunch
13:45:00 Pharmacogenomics and Personalised Medicine: From the Bench to the Bedside George Patrinos
14:15:00 Improving Probability of Technical Success: Why ‘Fishing Expeditions’ are Useful Leo Sahelijo
14:45:00 Afternoon refreshments
15:15:00 From Biomarker to Cleared/Approved Diagnostic: It’s Not Just Another Assay
15:45:00 Using Stratification Biomarkers to Improve Success of Clinical Trials Birgitte Søgaard
16:15:00 Case Study of Two Companion Tests for Therapeutic Vaccines in Development Philippe Ancian
16:45:00 Chairman’s closing remarks
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.